ESCRS - PO204 - Rate Of Complete Spectacle Independence With A Trifocal Iol: A Systematic Literature Review And Meta-Analysis

Rate Of Complete Spectacle Independence With A Trifocal Iol: A Systematic Literature Review And Meta-Analysis

Published 2022 - 40th Congress of the ESCRS

Reference: PO204 | Type: Free paper | DOI: 10.82333/wcn7-ke27

Authors: Dagny Zhu* 1 , Shijie Ren 2 , Kayla Mills 3 , Jessie Hull 4 , Mukesh Dhariwal 3

1NVISION Eye Centers,Rowland Heights,United States, 2The University of Sheffield,Sheffield ,United Kingdom, 3Global HEOR,Alcon Vision LLC,Fort Worth,United States, 4Alcon Vision LLC,Fort Worth,United States

Purpose

AcrySof IQ PanOptix (TFNTXX, TFATXX) is the first trifocal IOL launched in the USA in 2019. A systematic literature review and meta-analysis was conducted to identify and pool published evidence on complete spectacle independence rate in patients with bilateral implantation of TFNTXX/TFATXX.

Setting

Global

Methods

PubMed was searched from Jan 2017 to Sep 2021; congress abstract databases were also searched for recent studies that are yet to be published in peer-reviewed journals. Search terms included the technology name (TFNTXX, TFATXX, PanOptix) and “spectacle independence” or “visual outcomes”. A Bayesian random effects meta-analysis was conducted, providing a pooled estimate (posterior median treatment effect and its 95% credible interval (CI)) of complete spectacle independence rate among cataract or refractive lens exchange (RLE) surgery patients. Sub-group analyses evaluated spectacle independence across different distances (near, intermediate, far).

Results

Twenty-six unique clinical studies were identified (20 peer-reviewed publications, 6 congress presentations). Among patients who underwent cataract or RLE surgery with TFNTXX/TFATXX IOL, meta-analysis demonstrates complete spectacle independence rate of 92.8% (95% CI 0.89–0.96; N=19 studies). Sub-group analyses of pooled spectacle independence rates at each focal point of near, intermediate, and far among cataract and RLE surgery patients were 92.5%, 97.2%, and 95.9%, respectively (N=17). For studies reporting on patients who underwent cataract surgery only with TFNTXX/TFATXX, complete spectacle independence rate was 91.6% (95% CI 0.87–0.96;N=13).

Conclusions

This meta-analysis demonstrates at least 9 out of 10 patients receiving TFNTXX/TFATXX IOL for cataract or RLE surgery can be expected to achieve complete spectacle independence. This study provides informative data for clinicians and patients to feel confident in the use of TFNTXX/TFATXX as a trifocal IOL with high rate of complete spectacle independence.